Anti-HIV broadly neutralizing monoclonal antibody (bnabs) drug substance (DS) clinical trial material production and release

Ended Awarded Last action

Contract number
75N91018F00057
Awardee
Awarding agency
Obligated
$9,229,699

Award facts

Contract value 100% obligated
$9,229,698.87 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
NAICS code
561210 Facilities Support Services
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00006 $23,199
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Supplemental Agreement for work within scope P00003 $192,653
Supplemental Agreement for work within scope P00002 $0
Change Order P00001 $1,594,108
Original award $7,419,739

About this award

Written by GovTribe AI ·

Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., was awarded a cost-plus-fixed-fee delivery order valued at $9.23M by the National Institute of Allergy and Infectious Diseases (NIAID) on July 13, 2018, for the production and release of clinical trial material for anti-HIV broadly neutralizing monoclonal antibodies (bNAbs) drug substance. The work was performed in Frederick, Maryland, with an ultimate completion date of March 31, 2021. This award was not designated as a set-aside contract and leverages Leidos Biomedical Research Inc.'s established capabilities as a Federally Funded Research and Development Center (FFRDC) contractor supporting NIH and its institutes, including NIAID, in advanced biomedical research and therapeutic agent manufacturing.

The delivery order supports NIAID's efforts to advance HIV prevention and treatment research through the development of broadly neutralizing monoclonal antibodies, which represent a promising therapeutic and preventive approach for HIV management. Leidos Biomedical Research Inc. brings extensive experience in biopharmaceutical manufacturing and clinical trial support, including prior work on vaccine development, gene therapy candidates, and manufacturing of therapeutic agents for federal health agencies. As an FFRDC contractor, the company provides comprehensive research infrastructure and specialized scientific capabilities that enable efficient execution of complex federal biomedical research initiatives without requiring separate competitive procurements for discrete project components.

Quick answers

Who was awarded contract 75N91018F00057?

75N91018F00057 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on July 13, 2018.

How much is contract 75N91018F00057 worth?

The government has obligated $9,229,699 on 75N91018F00057.

Which agency awarded contract 75N91018F00057?

National Cancer Institute (National Institutes of Health) awarded 75N91018F00057, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).

Is contract 75N91018F00057 an order under another contract?

Yes. 75N91018F00057 is a delivery order under HHSN261201500003I, an indefinite delivery contract.

Was contract 75N91018F00057 competed?

The extent of competition for 75N91018F00057 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login